0001209191-22-053703.txt : 20221014
0001209191-22-053703.hdr.sgml : 20221014
20221014184616
ACCESSION NUMBER: 0001209191-22-053703
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220826
FILED AS OF DATE: 20221014
DATE AS OF CHANGE: 20221014
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hirano Patricia C
CENTRAL INDEX KEY: 0001766042
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36593
FILM NUMBER: 221312298
MAIL ADDRESS:
STREET 1: 1235 RADIO ROAD
STREET 2: SUITE 110
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC
CENTRAL INDEX KEY: 0001484565
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 770523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 203 REDWOOD SHORES PARKWAY
STREET 2: SUITE 500
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-213-8444
MAIL ADDRESS:
STREET 1: 203 REDWOOD SHORES PARKWAY
STREET 2: SUITE 500
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: Capnia, Inc.
DATE OF NAME CHANGE: 20100219
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-26
0
0001484565
SOLENO THERAPEUTICS INC
SLNO
0001766042
Hirano Patricia C
203 REDWOOD SHORES PKWY, STE 500
REDWOOD CITY
CA
94065
0
1
0
0
See Remarks
Common Stock
9273
D
Employee stock option (right to buy)
44.25
2027-04-19
Common Stock
266
266
D
Employee stock option (right to buy)
24.00
2028-02-07
Common Stock
6000
6000
D
Employee stock option (right to buy)
25.05
2029-01-24
Common Stock
4400
4400
D
Employee stock option (right to buy)
51.15
2030-05-18
Common Stock
2333
2333
D
Employee stock option (right to buy)
33.60
2031-01-08
Common Stock
21533
21533
D
Employee stock option (right to buy)
5.10
2032-01-28
Common Stock
7333
7333
D
Employee stock option (right to buy)
2.595
2032-07-27
Common Stock
13333
13333
D
Warrant (right to buy)
4.50
2022-03-31
2027-03-31
Common Stock
1333
1333
D
The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022.
Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
The per share exercise price and number of shares subject to the option reflect the 1-for-5 reverse stock split effected October 15, 2017 and the 1-for-15 reverse stock split effected August 26, 2022.
All of the shares subject to this option are fully vested and exercisable as of the date hereof.
The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022.
One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of January 24, 2019 (the "Vesting Commencement Date") and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of May 18, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
Twelve and one-half percent (12.5%) of the shares subject to the Option shall vest upon the date following the acceptance by the US FDA of an NDA submission for DCCR, twelve and one-half percent (12.5%) of the shares subject to the Option shall vest upon the submission by the Company to the European Medicines Agency European of an MAA for DCCR, and one forty-eighth (1/48th) of the remaining shares subject to the Option shall vest each month anniversary of January 8, 2021 (the "Vesting Commencement Date") on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
One forty-eighth (1/48th) of the shares subject to the Option shall vest on the first month anniversary of January 1, 2022 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
One fourth of the shares subject to the option shall vest on August 1, 2022 and each three-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.
The per share exercise price and number of shares subject to the warrant reflect the 1-for-15 reverse stock split effected August 26, 2022.
Officer title: Vice President, Regulatory Affairs
/s/ Anish Bhatnagar, Attorney-in-Fact
2022-10-14